Reduced risk
Novo Nordisk’s Ozempic Shows Promising Kidney Benefits for Diabetic Patients
Ozempic, Novo Nordisk, Chronic kidney disease, Cardiovascular events, Expanded use, Semaglutide, FLOW trial, Reduced risk, Type 2 diabetes
Actionable Insights Powered by AI
Ozempic, Novo Nordisk, Chronic kidney disease, Cardiovascular events, Expanded use, Semaglutide, FLOW trial, Reduced risk, Type 2 diabetes